Weekly Roundup 8 Dec 2023 Xenon’s $345 million public offering; EyePoint Pharmaceuticals’ trial success; gene therapy found to reduce liver cancer What’s been going on in the world of biotech of late? Find out with Labiotech’s weekly roundup of the latest biotech news. December 8, 2023 - 14 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Podcast 8 Dec 2023Can worms provide treatments for some diseases? U.S. company Holoclara is looking to tackle diseases through the development of worm-derived therapeutics. Allergic and autoimmune diseases were first described in the early 1900s, which Holoclara said is the same time that gut-resident worms such as the roundworm, Caenorhabditis elegans, were removed from people in industrialized countries. The company, led by CEO Andrea Choe, […] December 8, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2023 BIO-Europe 2023: top ten highlights The biopharma community met at Munich in Germany for BIO-Europe 2023, where attendees from across the world took part in networking events to foster collaboration, last month. With a turnout of nearly 6000 participants and more than 150 exhibitors, the event hosted a number of panel discussions. In collaboration with our parent company, life science […] December 7, 2023 - 24 minutesmins - By Dylan Kissane Share WhatsApp Twitter Linkedin Email
In Depth 7 Dec 2023 The biggest private biotech investments in November 2023 The companies Cambrian Innovation, Terremoto Biosciences, and VectorY Therapeutics bagged the biggest biotech investments in November 2023. Around the world, oncology and central nervous system players attracted the biggest funding rounds. As we edge closer to Christmas, biotech fundraising appears to be drying up a bit; there was a significant decrease in funding rounds in […] December 7, 2023 - 3 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2023 A gene editing milestone: The FDA approves CASGEVY, the first CRISPR-based therapy Still a relatively new technology, CRISPR has been heralded in recent years as having the potential to tackle a range of diseases. And now, it has finally proved its worth. In a world first, the U.S. Food and Drug Administration (FDA) has approved CASGEVY – the CRISPR-based gene therapy developed by Vertex Pharmaceuticals and CRISPR […] December 6, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
More News! 4 Dec 2023 FDA CAR-T cell therapy warning: Are T cells malignant? Chimeric antigen receptor (CAR) T cell therapies have emerged as groundbreaking treatments for various hematologic cancers, demonstrating remarkable efficacy in targeting specific cancer cells. However, recent concerns raised by the U.S. Food and Drug Administration (FDA) have sparked an investigation into potential risks associated with these therapies. The FDA CAR-T cell therapy warning comes at […] December 4, 2023 - 4 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 1 Dec 2023 Arvinas raises $350 million; Exonate’s trial reaps success; new cancer drugs discovered Here is Labiotech’s weekly roundup of the latest biotech news. Stay in the loop by subscribing to our newsletter for direct updates to your inbox. The latest biotech news in fundraising In the news this week, biotech Arvinas raises $350 million PIPE American protein degradation company Arvinas has bagged $350 million in a private placement (PIPE). The […] December 1, 2023 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Podcast 1 Dec 2023Ipsen drug gives hope for liver disease patients On the podcast this week, we are looking at recent advances in treating certain liver diseases. Jennifer Schranz is senior vice president and global head of rare diseases in the R&D division at Ipsen, and she discusses a breakthrough treatment for primary biliary cholangitis and cholestatic liver disease. What is primary biliary cholangitis? Primary biliary […] December 1, 2023 Share WhatsApp Twitter Linkedin Email
In Depth 30 Nov 2023 Could an Alzheimer’s vaccine make treatment more affordable? Alzheimer’s research has come a long way since the disease was first identified more than a century ago. Now, as treatments have been developed to reduce the harmful proteins in the brain that are associated with Alzheimer’s, vaccine trials are underway to eliminate these proteins. But how far along are these vaccines in the clinic? […] November 30, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Opinion 29 Nov 2023 Redefining drug development: the trailblazing evolution of the pharmaceutical industry Drug discovery and development is a long, costly, and high-risk process that takes over 10 to 15 years with an average cost of over $1 to $2 billion for each new drug to be approved for clinical use. For any pharmaceutical company or academic institution, it is a big achievement to advance a drug candidate […] November 29, 2023 - 9 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Nov 2023 Five companies shaping Texas’ growing biotech hubs Thanks to the U.S. government’s ambitious plans to advance American biotech and biomanufacturing, Texas’ life sciences hubs, particularly in Dallas and Houston, are now one of many in the country that are currently thriving. In this article, we take a closer look at several biotech companies in Texas taking advantage of the additional investment in […] November 28, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 27 Nov 2023 How are R&D Tax Incentives shaping Australia’s biotech future? Research and development (R&D) stands as a cornerstone for driving innovation, particularly within the biotech industry. The pivotal role of R&D extends beyond immediate commercial implications and encompasses a broader spectrum of societal and economic benefits. R&D represents significant expense, and if big companies can afford the risk, it may not be the case for […] November 27, 2023 - 5 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email